ClinicalTrials.gg
CompletedNCT02478463Updated Jun 22, 2020Results posted

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

A Phase 1 interventional study of Cabotegravir tablet 30 mg once daily for 28 days. and Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1. in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-22.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
30th of 36
19 · median 200
Started
2017
with 3 others
Phase 1
10 of 36
none open now
Registered
9th of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 30th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 1, and was the 9th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

Cabotegravir (CAB) long-acting (LA) is a promising candidate for human immunodeficiency virus (HIV) pre exposure prophylaxis (PrEP) due to its potent antiretroviral activity and infrequent dosing requirements. Currently, the CAB concentrations achieved in the anatomical sites associated with sexual HIV transmission following the proposed 600 milligram (mg) intramuscular (IM) PrEP dose are unknown. These data will enhance our understanding of CAB distribution to the anatomical mucosal tissue believed to be relevant to sexual HIV-1 transmission and supplement the data to support future PrEP clinical trial development. The primary objective is to determine the PK concentrations of CAB following LA administration in plasma and in vaginal tissue (VT), cervical tissue (CT), and cervicovaginal fluid (CVF) in healthy women and in rectal tissue (RT) and rectal fluid (RF) in healthy men and women following a single 600 mg IM dose. This will be a Phase 1, open label study in healthy subjects to assess the pharmacokinetics of CAB LA in the plasma and mucosal locations associated with sexual HIV-1 transmission: VT, CT, CVF, RT and RF. The study will consist of a screening period, a 28-day oral lead-in phase at a dose of 30 mg per day followed by a 14-42 day washout period, and a single dose of CAB LA 600 mg as an IM (intragluteal) injection with compartmental pharmacokinetic (PK) sampling for up to 12 weeks. Subjects will return for safety assessments and plasma PK sampling at Week 24 and Week 36 post-injection and undergo a follow-up/withdrawal visit at Week 52 post-injection.

03

Conditions studied

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Browse trials for

Keywords

  • Cabotegravir
  • Pharmacokinetic
  • Healthy Adult Volunteers
  • GSK1265744
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

This study's enrollment of 19 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 and 55 years of age inclusive, at the time of signing the .
  • Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
  • A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the medical monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. A single repeat of a procedure or lab parameter is allowed to determine eligibility.
  • Body weight >= 40 kilogram (kg) and (BMI) within the range 18.5 to 35 kg /meter square (inclusive).
  • Male or female
  • A female subject is eligible to participate if she is pre-menopausal, has an intact uterus and cervix, AND is not pregnant (as confirmed by a negative human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies: a) Non- defined as: Pre-menopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Documented Bilateral Oophorectomy. b)Reproductive potential and agrees to follow one of the options listed below in the GlaxoSmithKline (GSK) Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study medication and until at least five terminal half-lives OR until any continuing pharmacologic effect has ended, whichever is longer (can be up to 66 weeks on study) after the last dose of study medication and completion of the follow-up visit. Female subjects desiring pregnancy or foresee that they might wish to become pregnant within 52 weeks of receiving a CAB LA injection must be excluded. All subjects participating in the study must be counseled on safe sexual practices including the use of effective barrier methods to minimize risk of transmission.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Liver Function: or AST > (ULN)
  • Total >ULN (isolated total bilirubin >ULN is acceptable if total bilirubin is fractionated and direct bilirubin \<35%)
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • (QTc) Interval: QTc > 450 milliseconds (msec):

NOTES: The QTc is the QT interval corrected for heart rate according to Bazette's formula (QTcB), machine-read or manually over-read. QTcB will be used to determine eligibility for an individual subject. Exclusion criteria for screening (ECG) (a single repeat is allowed for eligibility determination): Heart rate (\<45 and >100 beats per minute (bpm) for males and \<50 and >100 bpm for females; QRS duration: >120 msec; QTc interval: >450 msec for males and females

  • The subject's systolic blood pressure is outside the range of 90-140 millimeter (mm) mercury (Hg), or diastolic blood pressure is outside the range of 45-90 mmHg.
  • History of cardiovascular disease including:

Evidence of previous myocardial infarction (pathologic Q waves, S-T segment changes (except early repolarization); History/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PCTA) or any clinically significant cardiac disease; Any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block (2nd degree [type II] or higher), Wolf Parkinson White [WPW] syndrome); Sinus pauses > 3 seconds.

  • Any significant arrhythmia which, in the opinion of the principal Investigator and GSK Medical Monitor, will interfere with the safety for the individual subject. Non-sustained (>=3 consecutive ventricular ectopic beats) or sustained ventricular tachycardia.
  • History of ongoing or clinically relevant seizure disorder within the previous 2 years, including subjects who have required treatment for seizures within this time period. A prior history of seizure, with a seizure free period of at least 2 years, off anti-epileptics, may be considered for enrolment if the investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the medical monitor prior to enrolment
  • Use of any concurrent prohibited medications as outlined in protocol
  • History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram (g) of alcohol: 12 ounces (360 milliliter [mL]) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
  • Inability or unwillingness to comply with lifestyle and/or dietary restrictions outlined in protocol.
  • High-risk behavior for infection which includes, but is not limited to, one of the following risk factors within six months before entering the study (Day 1 of the oral lead-in): Unprotected vaginal or anal sex with a known HIV infected person or a casual partner, engaged in sex work for money or drugs, acquired a sexually transmitted disease, high risk partner currently or in the previous six months or intravenous drug use.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
  • For subjects participating in magnetic resonance imaging (MRI) imaging: for MRI scanning (as assessed by local MRI safety questionnaire), which includes but is not limited to: a) Intracranial aneurysm clips (except Sugita) or other non-MRI compatible metallic objects; b) Intra- orbital metal fragments that have not been removed by a medical professional; c) Pacemakers or other implanted cardiac rhythm management devices and non-MRI compatible heart valves, d) Inner ear implants, e) History of claustrophobia
  • Positive surface antigen or positive hepatitis B core antibody with negative hepatitis B surface antibody test result at screening or within 3 months prior to first dose of study treatment.
  • Positive antibody test result at screening or within 3 months prior to first dose of study treatment
  • A positive pre-study drug/alcohol screen. A positive drug screen is permitted if due to a prescribed medication, provided that medication is not on the list of prohibited medications and approved by the investigator and medical monitor.
  • A positive test for HIV antibody.
  • A positive pre-study screen for sexually transmitted diseases including Neisseria gonorrhea or Chlamydia trachomatis, Trichomonas, syphilis, or an active Herpes simplex virus (HSV) genital lesion.
  • Presence of a tattoo or other dermatological condition overlying the buttocks which in the opinion of the investigator may interfere with the interpretation of injection site reactions.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Subject is mentally or legally incapacitated.

Additional Criteria for Female Subjects Only:

  • Any current medical conditions that in the opinion of the investigator may compromise the conduct or analysis of the genital tract sampling (e.g., active genital tract infection or lesions).
  • Inability to abstain from the use of intravaginal products (e.g. tampons, spermicides, lubricants, vaginal hygiene products, diaphragms) for 72 hours prior to the genital tract sample collection visits and for up to 72 hours after.
  • Inability to abstain from any sexual activity (e.g., vaginal intercourse, masturbation, and penetration of the vagina by penises, fingers, tampons, sex toys) for 72 hours prior to the genital tract sample collection visits and for up to 72 hours after.

Additional Criteria for Male Subjects and Female Subjects who consent to rectal PK sampling:

  • Any current medical conditions that in the opinion of the investigator may compromise the conduct or analysis of the rectal compartment sampling (e.g., active rectal compartment infection, lesions or disease).
  • Inability to abstain from the use of intrarectal products (e.g., suppositories, lubricants) for 72 hours prior to the rectal compartment sample collection visits and for up to 72 hours after.
  • Inability to abstain from any receptive anal sexual activity (e.g., anal receptive intercourse and penetration of the rectum by fingers, sex toys or other) for 72 hours prior to the rectal compartment sample collection visit and for up to 72 hours after.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Cabotegravir

    Subject will receive CAB 30 mg tablet once daily oral dose for 28 days (4 weeks) followed by a washout period of 14 to 42 days. After the washout, subject will receive a single dose of CAB LA 600 mg IM to gluteal region.

    Drug: Cabotegravir tablet 30 mg once daily for 28 days. · Drug: Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.

Interventions

  • GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237

  • DrugCabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.

    Drug page: Cabotegravir

    Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL \[600 mg\] total) IM given once on Day 1 of injection phase

07

What researchers measure

Primary outcomes

  1. Cabotegravir Concentration in Blood Plasma Following IM Administration

    Blood samples were collected to measure cabotegravir concentration in blood plasma following a single 600 mg IM dose at indicated time-points. Evaluable Pharmacokinetic (PK) Plasma Parameter Summary Population comprised of all participants who underwent plasma PK sampling following oral dose in treatment period 1 and IM injection in treatment period 2 and had evaluable PK parameters estimated and no major protocol deviation.

    Time frame: Day 1: Pre-dose and 4 hours; one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36 and 52 post-dose

  2. Cabotegravir Concentration in Vaginal Tissue Following IM Administration (Female Participants)

    Vaginal tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points. Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM) comprised of all participants who underwent sampling following oral dose in treatment period 1 and IM injection in treatment period 2 and have both evaluable PK and evaluable tissues-fluid parameters estimated in vaginal tissue/cervical tissue/cervicovaginal fluid/rectal tissue/rectal fluid.

    Time frame: One sample on Day 3 and Week 8 post-dose

  3. Cabotegravir Concentration in Cervical Tissue Following IM Administration (Female Participants)

    Cervical tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  4. Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)

    Cervicovaginal fluid samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  5. Cabotegravir Concentration in Rectal Tissue Following IM Administration

    Rectal tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  6. Cabotegravir Concentration in Rectal Fluid Following IM Administration

    Rectal fluid samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Secondary outcomes

  1. Ratio of Cabotegravir Concentration in Vaginal Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)

    Vaginal tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in vaginal tissue to cabotegravir concentration in blood plasma is presented.

    Time frame: One sample on Day 3 and Week 8 post-dose

  2. Ratio of Cabotegravir Concentration in Cervical Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)

    Cervical tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervical tissue to cabotegravir concentration in blood plasma is presented.

    Time frame: One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose

  3. Ratio of Cabotegravir Concentration in Cervicovaginal Fluid to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)

    Cervicovaginal fluid and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervicovaginal fluid to cabotegravir concentration in blood plasma is presented.

    Time frame: One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose

  4. Ratio of Cabotegravir Concentration in Cervical Tissue to Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)

    Cervical tissue and cervicovaginal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervical tissue to cabotegravir concentration in cervicovaginal fluid is presented.

    Time frame: One sample on Day 3, 8, Weeks 4, 8 and 12

  5. Ratio of Cabotegravir Concentration in Vaginal Tissue to Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)

    Vaginal tissue and cervicovaginal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in vaginal tissue to cabotegravir concentration in cervicovaginal fluid is presented.

    Time frame: One sample on Day 3 and Week 8 post-dose

  6. Ratio of Cabotegravir Concentration in Rectal Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration

    Rectal tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal tissue to cabotegravir concentration in blood plasma is presented.

    Time frame: One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose

  7. Ratio of Cabotegravir Concentration in Rectal Fluid to Cabotegravir Concentration in Blood Plasma Following IM Administration

    Rectal fluid and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal fluid to cabotegravir concentration in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  8. Ratio of Cabotegravir Concentration in Rectal Tissue to Cabotegravir Concentration in Rectal Fluid Following IM Administration

    Rectal tissue and rectal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal tissue to cabotegravir concentration in rectal fluid is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  9. Maximum Observed Concentration (Cmax) of Cabotegravir in Blood Plasma Following IM Administration

    Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose

  10. Cmax of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

    Cervical tissue samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  11. Cmax of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

    Cervicovaginal fluid samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  12. Cmax of Cabotegravir in Rectal Tissue Following IM Administration

    Rectal tissue samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  13. Cmax of Cabotegravir in Rectal Fluid Following IM Administration

    Rectal fluid samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  14. Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Time Point (AUC[0-last]) for Cabotegravir in Blood Plasma Following IM Administration

    Blood samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose, 4 hours, One sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose

  15. AUC(0-last) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

    Cervical tissue samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  16. AUC(0-last) of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

    Cervicovaginal fluid samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  17. AUC(0-last) for Cabotegravir in Rectal Tissue Following IM Administration

    Rectal tissue samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  18. AUC(0-last) for Cabotegravir in Rectal Fluid Following IM Administration

    Rectal fluid samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  19. Area Under the Concentration Time Curve From Time Zero to Infinity (AUC[0-inf]) for Cabotegravir in Blood Plasma Following IM Administration

    Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose

  20. AUC(0-inf) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

    Cervical tissue samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  21. AUC(0-inf) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

    Cervicovaginal fluid samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  22. AUC(0-inf) for Cabotegravir in Rectal Tissue Following IM Administration

    Rectal tissue samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  23. AUC(0-inf) for Cabotegravir in Rectal Fluid Following IM Administration

    Rectal fluid samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  24. Area Under the Concentration Time Curve From Time Zero to Week (WK) 4 (AUC[0-WK4]) for Cabotegravir in Blood Plasma Following IM Administration

    Blood samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8 and Week 4 post-dose

  25. AUC(0-WK4) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

    Cervical tissue samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8 and Week 4 post-dose

  26. AUC(0-WK4) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

    Cervicovaginal fluid samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8 and Week 4 post-dose

  27. AUC(0-WK4) for Cabotegravir in Rectal Tissue Following IM Administration

    Rectal tissue samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8 and Week 4 post-dose

  28. AUC(0-WK4) for Cabotegravir in Rectal Fluid Following IM Administration

    Rectal fluid samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8 and Week 4 post-dose

  29. Area Under the Concentration Time Curve From Time Zero to Week 8 (AUC[0-WK8]) for Cabotegravir in Blood Plasma Following IM Administration

    Blood samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4 and 8 post-dose

  30. AUC(0-WK8) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

    Cervical tissue samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose

  31. AUC(0-WK8) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

    Cervicovaginal fluid samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose

  32. AUC(0-WK8) for Cabotegravir in Rectal Tissue Following IM Administration

    Rectal tissue samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose

  33. AUC(0-WK8) for Cabotegravir in Rectal Fluid Following IM Administration

    Rectal fluid samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose

  34. Area Under the Concentration Time Curve From Time Zero to Week 12 (AUC[0-WK12]) for Cabotegravir in Blood Plasma Following IM Administration

    Blood samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8 and 12 post-dose

  35. AUC(0-WK12) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

    Cervical tissue samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  36. AUC(0-WK12) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

    Cervicovaginal fluid samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  37. AUC(0-WK12) for Cabotegravir in Rectal Tissue Following IM Administration

    Rectal tissue samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  38. AUC(0-WK12) for Cabotegravir in Rectal Fluid Following IM Administration

    Rectal fluid samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  39. Apparent Terminal Phase Half-life (t1/2) of Cabotegravir in Blood Plasma Following IM Administration

    Blood samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose

  40. t1/2 of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

    Cervical tissue samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  41. t1/2 of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

    Cervicovaginal fluid samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  42. t1/2 of Cabotegravir in Rectal Tissue Following IM Administration

    Rectal tissue samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  43. t1/2 of Cabotegravir in Rectal Fluid Following IM Administration

    Rectal fluid samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  44. Ratio of AUC(0-last) in Cervical Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

    Cervical tissue and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in cervical tissue to AUC(0-last) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  45. Ratio of AUC(0-last) in Rectal Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration

    Rectal tissue and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in rectal tissue to AUC(0-last) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  46. Ratio of AUC(0-inf) in Cervical Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

    Cervical tissue and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in cervical tissue to AUC(0-inf) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  47. Ratio of AUC(0-inf) in Rectal Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration

    Rectal tissue and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in rectal tissue to AUC(0-inf) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  48. Ratio of AUC(0-Wk4) in Cervical Tissue to AUC(0-Wk4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

    Cervical tissue and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in cervical tissue to AUC(0-WK4) in blood plasma is presented.

    Time frame: One sample on Days 3, 8 and Week 4 post-dose

  49. Ratio of AUC(0-Wk 4) in Rectal Tissue to AUC(0-Wk 4) in Blood Plasma for Cabotegravir Following IM Administration

    Rectal tissue and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in rectal tissue to AUC(0-WK4) in blood plasma is presented.

    Time frame: One sample on Days 3, 8 and Week 4 post-dose

  50. Ratio of AUC(0-WK8) in Cervical Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

    Cervical tissue and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in cervical tissue to AUC(0-WK8) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose

  51. Ratio of AUC(0-WK8) in Rectal Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration

    Rectal tissue and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in rectal tissue to AUC(0-WK8) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose

  52. Ratio of AUC(0-WK12) in Cervical Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

    Cervical tissue and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in cervical tissue to AUC(0-WK12) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  53. Ratio of AUC(0-WK12) in Rectal Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration

    Rectal tissue and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in rectal tissue to AUC(0-WK12) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  54. Ratio of AUC(0-last) in Cervicovaginal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration-female Participants

    Cervicovaginal fluid and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in cervicovaginal fluid to AUC(0-last) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  55. Ratio of AUC(0-last) in Rectal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration

    Rectal fluid and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in rectal fluid to AUC(0-last) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  56. Ratio of AUC(0-inf) in Cervicovaginal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

    Cervicovaginal fluid and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in cervicovaginal fluid to AUC(0-inf) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  57. Ratio of AUC(0-inf) in Rectal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration

    Rectal fluid and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in rectal fluid to AUC(0-inf) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  58. Ratio of AUC(0-WK4) in Cervicovaginal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

    Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in cervicovaginal fluid to AUC(0-WK4) in blood plasma is presented.

    Time frame: One sample on Days 3, 8 and Week 4 post-dose

  59. Ratio of AUC(0-WK4) in Rectal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration

    Rectal fluid and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in rectal fluid to AUC(0-WK4) in blood plasma is presented.

    Time frame: One sample on Days 3, 8 and Week 4 post-dose

  60. Ratio of AUC(0-WK8) in Cervicovaginal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

    Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in cervicovaginal fluid to AUC(0-WK8) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose

  61. Ratio of AUC(0-WK8) in Rectal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration

    Rectal fluid and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in rectal fluid to AUC(0-WK8) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose

  62. Ratio of AUC(0-WK12) in Cervicovaginal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

    Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in cervicovaginal fluid to AUC(0-WK12) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  63. Ratio of AUC(0-WK12) in Rectal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration

    Rectal fluid and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in rectal fluid to AUC(0-WK12) in blood plasma is presented.

    Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

  64. Cabotegravir Concentration in Vaginal Tissue Following Oral Administration (Female Participants)

    Vaginal tissue samples were collected to measure cabotegravir concentration in vaginal tissue following oral 30 mg dose at indicated time-points.

    Time frame: 24 hours post-dose on Day 28

  65. Cabotegravir Concentration in Cervical Tissue Following Oral Administration (Female Participants)

    Cervical tissue samples were collected to measure cabotegravir concentration in cervical tissue following oral 30 mg dose at indicated time-points.

    Time frame: 24 hours post-dose on Day 28

  66. Cabotegravir Concentration in Cervicovaginal Fluid Following Oral Administration (Female Participants)

    Cervicovaginal fluid samples were collected to measure cabotegravir concentration in cervicovaginal fluid following oral 30 mg dose at indicated time-points.

    Time frame: 24 hours post-dose on Day 28

  67. Cabotegravir Concentration in Rectal Tissue Following Oral Administration

    Rectal tissue samples were collected to measure cabotegravir concentration in rectal tissue following oral 30 mg dose at indicated time-points.

    Time frame: 24 hours post-dose on Day 28

  68. Cabotegravir Concentration in Rectal Fluid Following Oral Administration

    Rectal fluid samples were collected to measure cabotegravir concentration in rectal fluid following oral 30 mg dose at indicated time-points.

    Time frame: 24 hours post-dose on Day 28

  69. Cabotegravir Concentration in Blood Plasma Following Oral Administration

    Blood samples were collected to measure cabotegravir concentration in blood plasma following oral 30 mg dose at indicated time-points.

    Time frame: 24 hours post-dose on Day 28

  70. Number of Participants With Any Non-serious Adverse Event (Non-SAE) and Serious Adverse Events (SAE) Following Oral Administration of Cabotegravir

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment, associated with liver injury and impaired liver function was categorized as SAE. Number of participants with any non-SAE and SAE are presented.

    Time frame: Up to Day 29

  71. Number of Participants With Any Non-SAE and SAE Following IM Administration of Cabotegravir

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment, associated with liver injury and impaired liver function was categorized as SAE. Number of participants with any non-SAE and SAE are presented.

    Time frame: Up to Week 52

  72. Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Amino Transferase (AST) at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of clinical chemistry parameters; ALT, ALP and AST following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29

  73. Change From Baseline in ALT, ALP and AST at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of clinical chemistry parameters; ALT, ALP and AST following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

  74. Change From Baseline in Creatine Kinase at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of clinical chemistry parameter; creatine kinase following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29

  75. Change From Baseline in Creatine Kinase at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of clinical chemistry parameter; creatine kinase following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 8 and 12

  76. Change From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of clinical chemistry parameters; creatinine, direct bilirubin and total bilirubin following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29

  77. Change From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of clinical chemistry parameters; creatinine, direct bilirubin and total bilirubin following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

  78. Change From Baseline in Albumin and Total Protein at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of clinical chemistry parameters; albumin and total protein following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29

  79. Change From Baseline in Albumin and Total Protein at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of clinical chemistry parameters; albumin and total protein following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

  80. Change From Baseline in Calcium, Glucose, Potassium, Sodium and Urea Enzymatic Colorimetry at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of clinical chemistry parameters; calcium, glucose, potassium, sodium and urea enzymatic colorimetry (UEC) following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29

  81. Change From Baseline in Calcium, Glucose, Potassium, Sodium and UEC at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of clinical chemistry parameters; calcium, glucose, potassium, sodium and UEC following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

  82. Change From Baseline in Basophil Count, Eosinophil Count, Lymphocyte Count and Monocyte Count at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of hematology parameters; basophil count, eosinophil count, lymphocyte count and monocyte count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29

  83. Change From Baseline in Basophil Count, Eosinophil Count, Lymphocyte Count and Monocyte Count at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of hematology parameters; basophil count, eosinophil count, lymphocyte count and monocyte count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 4 and 8

  84. Change From Baseline in Total Neutrophil Count at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of hematology parameter; total neutrophils count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29

  85. Change From Baseline in Total Neutrophil Count at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of hematology parameters; total neutrophil count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

  86. Change From Baseline in Platelet Count and White Blood Cell (WBC) Count at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of hematology parameters; platelet count and WBC count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29

  87. Change From Baseline in Platelet Count and WBC Count at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of hematology parameters; platelet count and WBC count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

  88. Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of hematology parameters; hemoglobin and MCHC following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29

  89. Change From Baseline in Hemoglobin and MCHC at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of hematology parameters; hemoglobin and MCHC following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

  90. Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of hematology parameter; MCH following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29

  91. Change From Baseline in MCH at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of hematology parameter; MCH following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

  92. Change From Baseline in Mean Corpuscle Volume (MCV) at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of hematology parameter; MCV following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29

  93. Change From Baseline in MCV at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of hematology parameter; MCV following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

  94. Change From Baseline in Hematocrit at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of hematology parameter; hematocrit following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29

  95. Change From Baseline in Hematocrit at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of hematology parameter; hematocrit following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

  96. Change From Baseline in Red Blood Cell (RBC) Count at Indicated Time Points (Oral Dose)

    Blood samples were collected for the assessment of hematology parameter; RBC count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29

  97. Change From Baseline in RBC Count at Indicated Time Points (IM Dose)

    Blood samples were collected for the assessment of hematology parameter; RBC count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

  98. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time Points (Oral Dose)

    SBP and DBP were measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29

  99. Change From Baseline in SBP and DBP at Indicated Time Points (IM Dose)

    SBP and DBP were measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52

  100. Change From Baseline in Pulse Rate at Indicated Time Points (Oral Dose)

    Pulse rate was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29

  101. Change From Baseline in Pulse Rate at Indicated Time Points (IM Dose)

    Pulse rate was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52

  102. Change From Baseline in Body Temperature at Indicated Time Points (Oral Dose)

    Body temperature was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29

  103. Change From Baseline in Body Temperature at Indicated Time Points (IM Dose)

    Body temperature was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52

  104. Number of Participants With Abnormal Urinalysis Parameters Following Oral Administration of Cabotegravir

    Urinalysis included assessment of pH, glucose, protein, blood and ketones by dipstick method. This analysis was not planned and data was not collected and not captured in the database.

    Time frame: Up to Day 29

  105. Number of Participants With Abnormal Urinalysis Parameters Following IM Administration of Cabotegravir

    Urinalysis included assessment of pH, glucose, protein, blood and ketones by dipstick method. This analysis was not planned and data was not collected and not captured in the database.

    Time frame: Up to Week 52

08

Results

Posted Jun 22, 2020

Participant flow

This was a Phase 1, open label study in healthy participants to assess the pharmacokinetics of cabotegravir (CAB) long-acting (LA) in the blood plasma and anatomical tissues and secretions associated with sexual human immunodeficiency virus (HIV)-1 transmission. The study was conducted across two centers in the United States.

Treatment Period 1 (Up to Day 29)
Participant flow — Treatment Period 1 (Up to Day 29)
MilestoneCabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg
Started19
Completed18
Not completed1
Withdrew: Physician decision1
Washout Period (Up to 42 Days)
Participant flow — Washout Period (Up to 42 Days)
MilestoneCabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg
Started18
Completed17
Not completed1
Withdrew: Lost to follow-up1
Treatment Period 2 (Up to 52 Weeks)
Participant flow — Treatment Period 2 (Up to 52 Weeks)
MilestoneCabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg
Started17
Completed16
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryCabotegravir Concentration in Blood Plasma Following IM Administration

Blood samples were collected to measure cabotegravir concentration in blood plasma following a single 600 mg IM dose at indicated time-points. Evaluable Pharmacokinetic (PK) Plasma Parameter Summary Population comprised of all participants who underwent plasma PK sampling following oral dose in treatment period 1 and IM injection in treatment period 2 and had evaluable PK parameters estimated and no major protocol deviation.

Time frame:
Day 1: Pre-dose and 4 hours; one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36 and 52 post-dose
Reported as:
Mean · Micrograms per milliliter
Cabotegravir Concentration in Blood Plasma Following IM Administration
Micrograms per milliliterCabotegravir IM 600 mg
Day 1: Pre-dose, n=150.0000 ± NA
Day 1: 4 hours, n=150.2864 ± 0.10463
Day 3, n=153.2748 ± 1.74419
Day 5, n=155.1071 ± 3.09180
Day 8, n=155.0433 ± 2.92704
Week 4, n=152.5583 ± 1.00963
Week 8, n=150.9683 ± 0.73601
Week 12, n=150.3925 ± 0.40471
Week 24, n=150.0550 ± NA
Week 36, n=150.0213 ± NA
Week 52, n=140.0089 ± NA
PrimaryCabotegravir Concentration in Vaginal Tissue Following IM Administration (Female Participants)

Vaginal tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points. Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM) comprised of all participants who underwent sampling following oral dose in treatment period 1 and IM injection in treatment period 2 and have both evaluable PK and evaluable tissues-fluid parameters estimated in vaginal tissue/cervical tissue/cervicovaginal fluid/rectal tissue/rectal fluid.

Time frame:
One sample on Day 3 and Week 8 post-dose
Reported as:
Mean · Micrograms per milliliter
Cabotegravir Concentration in Vaginal Tissue Following IM Administration (Female Participants)
Micrograms per milliliterCabotegravir IM 600 mg
Day 30.5286 ± 0.48215
Week 80.1809 ± 0.14606
PrimaryCabotegravir Concentration in Cervical Tissue Following IM Administration (Female Participants)

Cervical tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Mean · Micrograms per milliliter
Cabotegravir Concentration in Cervical Tissue Following IM Administration (Female Participants)
Micrograms per milliliterCabotegravir IM 600 mg
Day 30.8016 ± 0.70126
Day 80.9261 ± 0.85513
Week 40.4409 ± 0.29216
Week 80.1570 ± 0.14909
Week 120.0460 ± NA
PrimaryCabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)

Cervicovaginal fluid samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Mean · Micrograms per milliliter
Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)
Micrograms per milliliterCabotegravir IM 600 mg
Day 30.6604 ± 0.91588
Day 80.6175 ± 0.59792
Week 40.3209 ± 0.37093
Week 80.0905 ± 0.14821
Week 120.0901 ± 0.18306
PrimaryCabotegravir Concentration in Rectal Tissue Following IM Administration

Rectal tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Mean · Micrograms per milliliter
Cabotegravir Concentration in Rectal Tissue Following IM Administration
Micrograms per milliliterCabotegravir IM 600 mg
Day 30.2824 ± 0.17814
Day 80.5146 ± 0.26514
Week 40.2620 ± 0.10476
Week 80.1037 ± 0.10050
Week 120.0348 ± NA
PrimaryCabotegravir Concentration in Rectal Fluid Following IM Administration

Rectal fluid samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Mean · Micrograms per milliliter
Cabotegravir Concentration in Rectal Fluid Following IM Administration
Micrograms per milliliterCabotegravir IM 600 mg
Day 31.3868 ± 1.88097
Day 83.2046 ± 2.68417
Week 45.2674 ± 7.99949
Week 80.3233 ± 0.22764
Week 120.7901 ± 1.75430
SecondaryRatio of Cabotegravir Concentration in Vaginal Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)

Vaginal tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in vaginal tissue to cabotegravir concentration in blood plasma is presented.

Time frame:
One sample on Day 3 and Week 8 post-dose
Reported as:
Geometric mean · Ratio
Ratio of Cabotegravir Concentration in Vaginal Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Day 30.128 ± 43.38
Week 80.199 ± 32.66
SecondaryRatio of Cabotegravir Concentration in Cervical Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)

Cervical tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervical tissue to cabotegravir concentration in blood plasma is presented.

Time frame:
One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of Cabotegravir Concentration in Cervical Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Day 30.203 ± 36.14
Day 80.174 ± 44.85
Week 40.139 ± 99.93
Week 80.139 ± 59.16
Week 120.101 ± 45.10
SecondaryRatio of Cabotegravir Concentration in Cervicovaginal Fluid to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)

Cervicovaginal fluid and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervicovaginal fluid to cabotegravir concentration in blood plasma is presented.

Time frame:
One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of Cabotegravir Concentration in Cervicovaginal Fluid to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Day 30.116 ± 174.76
Day 80.124 ± 73.53
Week 40.073 ± 277.59
Week 80.057 ± 101.03
Week 120.082 ± 112.91
SecondaryRatio of Cabotegravir Concentration in Cervical Tissue to Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)

Cervical tissue and cervicovaginal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervical tissue to cabotegravir concentration in cervicovaginal fluid is presented.

Time frame:
One sample on Day 3, 8, Weeks 4, 8 and 12
Reported as:
Geometric mean · Ratio
Ratio of Cabotegravir Concentration in Cervical Tissue to Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Day 31.738 ± 118.75
Day 81.405 ± 81.10
Week 41.883 ± 172.44
Week 82.785 ± 110.92
Week 121.195 ± 105.01
SecondaryRatio of Cabotegravir Concentration in Vaginal Tissue to Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)

Vaginal tissue and cervicovaginal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in vaginal tissue to cabotegravir concentration in cervicovaginal fluid is presented.

Time frame:
One sample on Day 3 and Week 8 post-dose
Reported as:
Geometric mean · Ratio
Ratio of Cabotegravir Concentration in Vaginal Tissue to Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Day 31.095 ± 233.20
Week 83.613 ± 115.25
SecondaryRatio of Cabotegravir Concentration in Rectal Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration

Rectal tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal tissue to cabotegravir concentration in blood plasma is presented.

Time frame:
One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of Cabotegravir Concentration in Rectal Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration
RatioCabotegravir IM 600 mg
Day 30.078 ± 43.13
Day 80.105 ± 22.92
Week 40.104 ± 18.79
Week 80.096 ± 27.81
Week 120.091 ± 38.62
SecondaryRatio of Cabotegravir Concentration in Rectal Fluid to Cabotegravir Concentration in Blood Plasma Following IM Administration

Rectal fluid and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal fluid to cabotegravir concentration in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of Cabotegravir Concentration in Rectal Fluid to Cabotegravir Concentration in Blood Plasma Following IM Administration
RatioCabotegravir IM 600 mg
Day 30.286 ± 157.60
Day 80.581 ± 140.37
Week 40.460 ± 923.37
Week 80.302 ± 140.54
Week 120.514 ± 185.97
SecondaryRatio of Cabotegravir Concentration in Rectal Tissue to Cabotegravir Concentration in Rectal Fluid Following IM Administration

Rectal tissue and rectal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal tissue to cabotegravir concentration in rectal fluid is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of Cabotegravir Concentration in Rectal Tissue to Cabotegravir Concentration in Rectal Fluid Following IM Administration
RatioCabotegravir IM 600 mg
Day 3, n=110.271 ± 150.25
Day 8, n=120.185 ± 140.92
Week 4, n=120.230 ± 1082.13
Week 8, n=120.366 ± 133.20
Week 12, n=120.093 ± 294.16
SecondaryMaximum Observed Concentration (Cmax) of Cabotegravir in Blood Plasma Following IM Administration

Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Observed Concentration (Cmax) of Cabotegravir in Blood Plasma Following IM Administration
Micrograms per milliliterCabotegravir IM 600 mg
Maximum Observed Concentration (Cmax) of Cabotegravir in Blood Plasma Following IM Administration5.04 ± 62.0
SecondaryCmax of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

Cervical tissue samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Cmax of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Micrograms per milliliterCabotegravir IM 600 mg
Cmax of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)0.81 ± 105.0
SecondaryCmax of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

Cervicovaginal fluid samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Cmax of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Micrograms per milliliterCabotegravir IM 600 mg
Cmax of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)0.55 ± 118.3
SecondaryCmax of Cabotegravir in Rectal Tissue Following IM Administration

Rectal tissue samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Cmax of Cabotegravir in Rectal Tissue Following IM Administration
Micrograms per milliliterCabotegravir IM 600 mg
Cmax of Cabotegravir in Rectal Tissue Following IM Administration0.50 ± 47.0
SecondaryCmax of Cabotegravir in Rectal Fluid Following IM Administration

Rectal fluid samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Cmax of Cabotegravir in Rectal Fluid Following IM Administration
Micrograms per milliliterCabotegravir IM 600 mg
Cmax of Cabotegravir in Rectal Fluid Following IM Administration3.27 ± 171.9
SecondaryArea Under the Concentration Time Curve From Time Zero to Last Quantifiable Time Point (AUC[0-last]) for Cabotegravir in Blood Plasma Following IM Administration

Blood samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose, 4 hours, One sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Time Point (AUC[0-last]) for Cabotegravir in Blood Plasma Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Time Point (AUC[0-last]) for Cabotegravir in Blood Plasma Following IM Administration3992.25 ± 24.5
SecondaryAUC(0-last) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

Cervical tissue samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-last) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-last) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)522.73 ± 77.0
SecondaryAUC(0-last) of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

Cervicovaginal fluid samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-last) of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-last) of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)324.33 ± 121.4
SecondaryAUC(0-last) for Cabotegravir in Rectal Tissue Following IM Administration

Rectal tissue samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-last) for Cabotegravir in Rectal Tissue Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-last) for Cabotegravir in Rectal Tissue Following IM Administration347.73 ± 35.5
SecondaryAUC(0-last) for Cabotegravir in Rectal Fluid Following IM Administration

Rectal fluid samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-last) for Cabotegravir in Rectal Fluid Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-last) for Cabotegravir in Rectal Fluid Following IM Administration1841.23 ± 193.8
SecondaryArea Under the Concentration Time Curve From Time Zero to Infinity (AUC[0-inf]) for Cabotegravir in Blood Plasma Following IM Administration

Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
Area Under the Concentration Time Curve From Time Zero to Infinity (AUC[0-inf]) for Cabotegravir in Blood Plasma Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
Area Under the Concentration Time Curve From Time Zero to Infinity (AUC[0-inf]) for Cabotegravir in Blood Plasma Following IM Administration4172.17 ± 23.9
SecondaryAUC(0-inf) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

Cervical tissue samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-inf) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-inf) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)695.72 ± NA
SecondaryAUC(0-inf) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

Cervicovaginal fluid samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-inf) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-inf) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)399.07 ± 99.9
SecondaryAUC(0-inf) for Cabotegravir in Rectal Tissue Following IM Administration

Rectal tissue samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-inf) for Cabotegravir in Rectal Tissue Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-inf) for Cabotegravir in Rectal Tissue Following IM Administration291.98 ± 34.6
SecondaryAUC(0-inf) for Cabotegravir in Rectal Fluid Following IM Administration

Rectal fluid samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-inf) for Cabotegravir in Rectal Fluid Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-inf) for Cabotegravir in Rectal Fluid Following IM Administration850.05 ± 42.7
SecondaryArea Under the Concentration Time Curve From Time Zero to Week (WK) 4 (AUC[0-WK4]) for Cabotegravir in Blood Plasma Following IM Administration

Blood samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8 and Week 4 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
Area Under the Concentration Time Curve From Time Zero to Week (WK) 4 (AUC[0-WK4]) for Cabotegravir in Blood Plasma Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
Area Under the Concentration Time Curve From Time Zero to Week (WK) 4 (AUC[0-WK4]) for Cabotegravir in Blood Plasma Following IM Administration2141.91 ± 59.2
SecondaryAUC(0-WK4) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

Cervical tissue samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8 and Week 4 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-WK4) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-WK4) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)277.48 ± 103.6
SecondaryAUC(0-WK4) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

Cervicovaginal fluid samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8 and Week 4 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-WK4) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-WK4) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)203.32 ± 125.5
SecondaryAUC(0-WK4) for Cabotegravir in Rectal Tissue Following IM Administration

Rectal tissue samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8 and Week 4 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-WK4) for Cabotegravir in Rectal Tissue Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-WK4) for Cabotegravir in Rectal Tissue Following IM Administration206.28 ± 57.2
SecondaryAUC(0-WK4) for Cabotegravir in Rectal Fluid Following IM Administration

Rectal fluid samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8 and Week 4 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-WK4) for Cabotegravir in Rectal Fluid Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-WK4) for Cabotegravir in Rectal Fluid Following IM Administration1170.49 ± 192.1
SecondaryArea Under the Concentration Time Curve From Time Zero to Week 8 (AUC[0-WK8]) for Cabotegravir in Blood Plasma Following IM Administration

Blood samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4 and 8 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
Area Under the Concentration Time Curve From Time Zero to Week 8 (AUC[0-WK8]) for Cabotegravir in Blood Plasma Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
Area Under the Concentration Time Curve From Time Zero to Week 8 (AUC[0-WK8]) for Cabotegravir in Blood Plasma Following IM Administration3213.62 ± 40.1
SecondaryAUC(0-WK8) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

Cervical tissue samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4 and 8 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-WK8) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-WK8) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)364.74 ± 85.2
SecondaryAUC(0-WK8) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

Cervicovaginal fluid samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4 and 8 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-WK8) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-WK8) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)281.60 ± 124.8
SecondaryAUC(0-WK8) for Cabotegravir in Rectal Tissue Following IM Administration

Rectal tissue samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4 and 8 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-WK8) for Cabotegravir in Rectal Tissue Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-WK8) for Cabotegravir in Rectal Tissue Following IM Administration287.35 ± 38.7
SecondaryAUC(0-WK8) for Cabotegravir in Rectal Fluid Following IM Administration

Rectal fluid samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4 and 8 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-WK8) for Cabotegravir in Rectal Fluid Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-WK8) for Cabotegravir in Rectal Fluid Following IM Administration1575.54 ± 202.9
SecondaryArea Under the Concentration Time Curve From Time Zero to Week 12 (AUC[0-WK12]) for Cabotegravir in Blood Plasma Following IM Administration

Blood samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
Area Under the Concentration Time Curve From Time Zero to Week 12 (AUC[0-WK12]) for Cabotegravir in Blood Plasma Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
Area Under the Concentration Time Curve From Time Zero to Week 12 (AUC[0-WK12]) for Cabotegravir in Blood Plasma Following IM Administration3639.01 ± 35.6
SecondaryAUC(0-WK12) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

Cervical tissue samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-WK12) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-WK12) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)349.98 ± 78.9
SecondaryAUC(0-WK12) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

Cervicovaginal fluid samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-WK12) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-WK12) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)380.92 ± 107.8
SecondaryAUC(0-WK12) for Cabotegravir in Rectal Tissue Following IM Administration

Rectal tissue samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-WK12) for Cabotegravir in Rectal Tissue Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-WK12) for Cabotegravir in Rectal Tissue Following IM Administration323.91 ± 54.8
SecondaryAUC(0-WK12) for Cabotegravir in Rectal Fluid Following IM Administration

Rectal fluid samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours*microgram per milliliter
AUC(0-WK12) for Cabotegravir in Rectal Fluid Following IM Administration
Hours*microgram per milliliterCabotegravir IM 600 mg
AUC(0-WK12) for Cabotegravir in Rectal Fluid Following IM Administration1345.13 ± 137.7
SecondaryApparent Terminal Phase Half-life (t1/2) of Cabotegravir in Blood Plasma Following IM Administration

Blood samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose
Reported as:
Geometric mean · Hours
Apparent Terminal Phase Half-life (t1/2) of Cabotegravir in Blood Plasma Following IM Administration
HoursCabotegravir IM 600 mg
Apparent Terminal Phase Half-life (t1/2) of Cabotegravir in Blood Plasma Following IM Administration459.53 ± 81.4
Secondaryt1/2 of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)

Cervical tissue samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours
t1/2 of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
HoursCabotegravir IM 600 mg
t1/2 of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)363.41 ± NA
Secondaryt1/2 of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)

Cervicovaginal fluid samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours
t1/2 of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
HoursCabotegravir IM 600 mg
t1/2 of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)355.83 ± 79.4
Secondaryt1/2 of Cabotegravir in Rectal Tissue Following IM Administration

Rectal tissue samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours
t1/2 of Cabotegravir in Rectal Tissue Following IM Administration
HoursCabotegravir IM 600 mg
t1/2 of Cabotegravir in Rectal Tissue Following IM Administration567.48 ± 23.3
Secondaryt1/2 of Cabotegravir in Rectal Fluid Following IM Administration

Rectal fluid samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Hours
t1/2 of Cabotegravir in Rectal Fluid Following IM Administration
HoursCabotegravir IM 600 mg
t1/2 of Cabotegravir in Rectal Fluid Following IM Administration306.58 ± 3.5
SecondaryRatio of AUC(0-last) in Cervical Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

Cervical tissue and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in cervical tissue to AUC(0-last) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-last) in Cervical Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Ratio of AUC(0-last) in Cervical Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)0.1215 ± 64.86
SecondaryRatio of AUC(0-last) in Rectal Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration

Rectal tissue and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in rectal tissue to AUC(0-last) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-last) in Rectal Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration
RatioCabotegravir IM 600 mg
Ratio of AUC(0-last) in Rectal Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration0.0849 ± 21.13
SecondaryRatio of AUC(0-inf) in Cervical Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

Cervical tissue and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in cervical tissue to AUC(0-inf) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-inf) in Cervical Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Ratio of AUC(0-inf) in Cervical Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)0.1943 ± NA
SecondaryRatio of AUC(0-inf) in Rectal Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration

Rectal tissue and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in rectal tissue to AUC(0-inf) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-inf) in Rectal Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration
RatioCabotegravir IM 600 mg
Ratio of AUC(0-inf) in Rectal Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration0.0766 ± 42.26
SecondaryRatio of AUC(0-Wk4) in Cervical Tissue to AUC(0-Wk4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

Cervical tissue and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in cervical tissue to AUC(0-WK4) in blood plasma is presented.

Time frame:
One sample on Days 3, 8 and Week 4 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-Wk4) in Cervical Tissue to AUC(0-Wk4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Ratio of AUC(0-Wk4) in Cervical Tissue to AUC(0-Wk4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)0.1553 ± 50.33
SecondaryRatio of AUC(0-Wk 4) in Rectal Tissue to AUC(0-Wk 4) in Blood Plasma for Cabotegravir Following IM Administration

Rectal tissue and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in rectal tissue to AUC(0-WK4) in blood plasma is presented.

Time frame:
One sample on Days 3, 8 and Week 4 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-Wk 4) in Rectal Tissue to AUC(0-Wk 4) in Blood Plasma for Cabotegravir Following IM Administration
RatioCabotegravir IM 600 mg
Ratio of AUC(0-Wk 4) in Rectal Tissue to AUC(0-Wk 4) in Blood Plasma for Cabotegravir Following IM Administration0.1000 ± 19.30
SecondaryRatio of AUC(0-WK8) in Cervical Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

Cervical tissue and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in cervical tissue to AUC(0-WK8) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4 and 8 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-WK8) in Cervical Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Ratio of AUC(0-WK8) in Cervical Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)0.1492 ± 52.30
SecondaryRatio of AUC(0-WK8) in Rectal Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration

Rectal tissue and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in rectal tissue to AUC(0-WK8) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4 and 8 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-WK8) in Rectal Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration
RatioCabotegravir IM 600 mg
Ratio of AUC(0-WK8) in Rectal Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration0.1062 ± 17.46
SecondaryRatio of AUC(0-WK12) in Cervical Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

Cervical tissue and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in cervical tissue to AUC(0-WK12) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-WK12) in Cervical Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Ratio of AUC(0-WK12) in Cervical Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)0.1230 ± 48.22
SecondaryRatio of AUC(0-WK12) in Rectal Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration

Rectal tissue and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in rectal tissue to AUC(0-WK12) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-WK12) in Rectal Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration
RatioCabotegravir IM 600 mg
Ratio of AUC(0-WK12) in Rectal Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration0.1089 ± 13.50
SecondaryRatio of AUC(0-last) in Cervicovaginal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration-female Participants

Cervicovaginal fluid and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in cervicovaginal fluid to AUC(0-last) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-last) in Cervicovaginal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration-female Participants
RatioCabotegravir IM 600 mg
Ratio of AUC(0-last) in Cervicovaginal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration-female Participants0.0754 ± 99.37
SecondaryRatio of AUC(0-last) in Rectal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration

Rectal fluid and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in rectal fluid to AUC(0-last) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-last) in Rectal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration
RatioCabotegravir IM 600 mg
Ratio of AUC(0-last) in Rectal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration0.4445 ± 204.26
SecondaryRatio of AUC(0-inf) in Cervicovaginal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

Cervicovaginal fluid and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in cervicovaginal fluid to AUC(0-inf) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-inf) in Cervicovaginal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Ratio of AUC(0-inf) in Cervicovaginal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)0.0857 ± 99.10
SecondaryRatio of AUC(0-inf) in Rectal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration

Rectal fluid and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in rectal fluid to AUC(0-inf) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-inf) in Rectal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration
RatioCabotegravir IM 600 mg
Ratio of AUC(0-inf) in Rectal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration0.1949 ± 80.06
SecondaryRatio of AUC(0-WK4) in Cervicovaginal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in cervicovaginal fluid to AUC(0-WK4) in blood plasma is presented.

Time frame:
One sample on Days 3, 8 and Week 4 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-WK4) in Cervicovaginal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Ratio of AUC(0-WK4) in Cervicovaginal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)0.1032 ± 119.71
SecondaryRatio of AUC(0-WK4) in Rectal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration

Rectal fluid and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in rectal fluid to AUC(0-WK4) in blood plasma is presented.

Time frame:
One sample on Days 3, 8 and Week 4 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-WK4) in Rectal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration
RatioCabotegravir IM 600 mg
Ratio of AUC(0-WK4) in Rectal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration0.5452 ± 223.58
SecondaryRatio of AUC(0-WK8) in Cervicovaginal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in cervicovaginal fluid to AUC(0-WK8) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4 and 8 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-WK8) in Cervicovaginal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Ratio of AUC(0-WK8) in Cervicovaginal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)0.0925 ± 124.99
SecondaryRatio of AUC(0-WK8) in Rectal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration

Rectal fluid and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in rectal fluid to AUC(0-WK8) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4 and 8 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-WK8) in Rectal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration
RatioCabotegravir IM 600 mg
Ratio of AUC(0-WK8) in Rectal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration0.4845 ± 212.20
SecondaryRatio of AUC(0-WK12) in Cervicovaginal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)

Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in cervicovaginal fluid to AUC(0-WK12) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-WK12) in Cervicovaginal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
RatioCabotegravir IM 600 mg
Ratio of AUC(0-WK12) in Cervicovaginal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)0.0867 ± 99.56
SecondaryRatio of AUC(0-WK12) in Rectal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration

Rectal fluid and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in rectal fluid to AUC(0-WK12) in blood plasma is presented.

Time frame:
One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Reported as:
Geometric mean · Ratio
Ratio of AUC(0-WK12) in Rectal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration
RatioCabotegravir IM 600 mg
Ratio of AUC(0-WK12) in Rectal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration0.3863 ± 154.56
SecondaryCabotegravir Concentration in Vaginal Tissue Following Oral Administration (Female Participants)

Vaginal tissue samples were collected to measure cabotegravir concentration in vaginal tissue following oral 30 mg dose at indicated time-points.

Time frame:
24 hours post-dose on Day 28
Reported as:
Mean · Micrograms per milliliter
Cabotegravir Concentration in Vaginal Tissue Following Oral Administration (Female Participants)
Micrograms per milliliterCabotegravir Oral 30 mg
Cabotegravir Concentration in Vaginal Tissue Following Oral Administration (Female Participants)0.7477 ± 0.50171
SecondaryCabotegravir Concentration in Cervical Tissue Following Oral Administration (Female Participants)

Cervical tissue samples were collected to measure cabotegravir concentration in cervical tissue following oral 30 mg dose at indicated time-points.

Time frame:
24 hours post-dose on Day 28
Reported as:
Mean · Micrograms per milliliter
Cabotegravir Concentration in Cervical Tissue Following Oral Administration (Female Participants)
Micrograms per milliliterCabotegravir Oral 30 mg
Cabotegravir Concentration in Cervical Tissue Following Oral Administration (Female Participants)1.1009 ± 0.53987
SecondaryCabotegravir Concentration in Cervicovaginal Fluid Following Oral Administration (Female Participants)

Cervicovaginal fluid samples were collected to measure cabotegravir concentration in cervicovaginal fluid following oral 30 mg dose at indicated time-points.

Time frame:
24 hours post-dose on Day 28
Reported as:
Mean · Micrograms per milliliter
Cabotegravir Concentration in Cervicovaginal Fluid Following Oral Administration (Female Participants)
Micrograms per milliliterCabotegravir Oral 30 mg
Cabotegravir Concentration in Cervicovaginal Fluid Following Oral Administration (Female Participants)0.8959 ± 0.95662
SecondaryCabotegravir Concentration in Rectal Tissue Following Oral Administration

Rectal tissue samples were collected to measure cabotegravir concentration in rectal tissue following oral 30 mg dose at indicated time-points.

Time frame:
24 hours post-dose on Day 28
Reported as:
Mean · Micrograms per milliliter
Cabotegravir Concentration in Rectal Tissue Following Oral Administration
Micrograms per milliliterCabotegravir Oral 30 mg
Cabotegravir Concentration in Rectal Tissue Following Oral Administration0.6104 ± 0.24854
SecondaryCabotegravir Concentration in Rectal Fluid Following Oral Administration

Rectal fluid samples were collected to measure cabotegravir concentration in rectal fluid following oral 30 mg dose at indicated time-points.

Time frame:
24 hours post-dose on Day 28
Reported as:
Mean · Micrograms per milliliter
Cabotegravir Concentration in Rectal Fluid Following Oral Administration
Micrograms per milliliterCabotegravir Oral 30 mg
Cabotegravir Concentration in Rectal Fluid Following Oral Administration5.5457 ± 6.41639
SecondaryCabotegravir Concentration in Blood Plasma Following Oral Administration

Blood samples were collected to measure cabotegravir concentration in blood plasma following oral 30 mg dose at indicated time-points.

Time frame:
24 hours post-dose on Day 28
Reported as:
Mean · Micrograms per milliliter
Cabotegravir Concentration in Blood Plasma Following Oral Administration
Micrograms per milliliterCabotegravir Oral 30 mg
Cabotegravir Concentration in Blood Plasma Following Oral Administration5.7313 ± 2.08899
SecondaryNumber of Participants With Any Non-serious Adverse Event (Non-SAE) and Serious Adverse Events (SAE) Following Oral Administration of Cabotegravir

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment, associated with liver injury and impaired liver function was categorized as SAE. Number of participants with any non-SAE and SAE are presented.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Any Non-serious Adverse Event (Non-SAE) and Serious Adverse Events (SAE) Following Oral Administration of Cabotegravir
ParticipantsCabotegravir Oral 30 mg
Any Non-SAE10
Any SAE0
SecondaryNumber of Participants With Any Non-SAE and SAE Following IM Administration of Cabotegravir

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment, associated with liver injury and impaired liver function was categorized as SAE. Number of participants with any non-SAE and SAE are presented.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Any Non-SAE and SAE Following IM Administration of Cabotegravir
ParticipantsCabotegravir IM 600 mg
Any Non-SAE17
Any SAE2
SecondaryChange From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Amino Transferase (AST) at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of clinical chemistry parameters; ALT, ALP and AST following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 14 and 29
Reported as:
Mean · International units per Liter
Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Amino Transferase (AST) at Indicated Time Points (Oral Dose)
International units per LiterCabotegravir Oral 30 mg
ALT, Day 141.7 ± 8.98
ALT, Day 293.5 ± 10.12
ALP, Day 14-0.2 ± 6.44
ALP, Day 29-0.4 ± 3.24
AST, Day 14-0.3 ± 3.60
AST, Day 291.1 ± 6.14
SecondaryChange From Baseline in ALT, ALP and AST at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of clinical chemistry parameters; ALT, ALP and AST following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Reported as:
Mean · International units per Liter
Change From Baseline in ALT, ALP and AST at Indicated Time Points (IM Dose)
International units per LiterCabotegravir IM 600 mg
ALT, Week 4, n=17-0.2 ± 4.05
ALT, Week 8, n=16-0.8 ± 5.33
ALT, Week 12, n=16-1.4 ± 3.81
ALP, Week 4, n=152.1 ± 6.39
ALP, Week 8, n=160.6 ± 8.43
ALP, Week 12, n=161.3 ± 6.57
AST, Week 4, n=170.1 ± 2.87
AST, Week 8, n=160.1 ± 3.76
AST, Week 12, n=16-0.1 ± 3.50
SecondaryChange From Baseline in Creatine Kinase at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of clinical chemistry parameter; creatine kinase following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 14 and 29
Reported as:
Mean · International units per Liter
Change From Baseline in Creatine Kinase at Indicated Time Points (Oral Dose)
International units per LiterCabotegravir Oral 30 mg
Day 14-19.9 ± 27.23
Day 29-8.9 ± 46.56
SecondaryChange From Baseline in Creatine Kinase at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of clinical chemistry parameter; creatine kinase following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 8 and 12
Reported as:
Mean · International units per Liter
Change From Baseline in Creatine Kinase at Indicated Time Points (IM Dose)
International units per LiterCabotegravir IM 600 mg
Week 819.6 ± 67.42
Week 1222.2 ± 92.09
SecondaryChange From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of clinical chemistry parameters; creatinine, direct bilirubin and total bilirubin following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 14 and 29
Reported as:
Mean · Micromoles per liter
Change From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at Indicated Time Points (Oral Dose)
Micromoles per literCabotegravir Oral 30 mg
Creatinine, Day 14, n=180.491 ± 5.6500
Creatinine, Day 29, n=18-0.491 ± 7.0929
Direct bilirubin, Day 14, n=11-0.311 ± 0.6917
Direct bilirubin, Day 29, n=120.428 ± 0.7734
Total bilirubin, Day 14, n=16-1.282 ± 1.9245
Total bilirubin, Day 29, n=160.000 ± 2.7217
SecondaryChange From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of clinical chemistry parameters; creatinine, direct bilirubin and total bilirubin following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Reported as:
Mean · Micromoles per liter
Change From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at Indicated Time Points (IM Dose)
Micromoles per literCabotegravir IM 600 mg
Creatinine, Week 4, n=17-3.640 ± 8.3037
Creatinine, Week 8, n=16-5.525 ± 5.4732
Creatinine, Week 12, n=16-3.315 ± 8.4637
Direct bilirubin, Week 4, n=10-0.171 ± 0.5407
Direct bilirubin, Week 8, n=100.171 ± 1.2617
Direct bilirubin, Week 12, n=90.190 ± 1.3368
Total bilirubin, Week 4, n=160.641 ± 3.1142
Total bilirubin, Week 8, n=150.114 ± 4.2118
Total bilirubin, Week 12, n=141.099 ± 4.5789
SecondaryChange From Baseline in Albumin and Total Protein at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of clinical chemistry parameters; albumin and total protein following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 14 and 29
Reported as:
Mean · Grams per liter
Change From Baseline in Albumin and Total Protein at Indicated Time Points (Oral Dose)
Grams per literCabotegravir Oral 30 mg
Albumin, Day 14-0.6 ± 2.85
Albumin, Day 29-0.3 ± 1.53
Total protein, Day 14-1.7 ± 3.48
Total protein, Day 29-1.4 ± 2.23
SecondaryChange From Baseline in Albumin and Total Protein at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of clinical chemistry parameters; albumin and total protein following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Reported as:
Mean · Grams per liter
Change From Baseline in Albumin and Total Protein at Indicated Time Points (IM Dose)
Grams per literCabotegravir IM 600 mg
Albumin, Week 4, n=170.3 ± 2.66
Albumin, Week 8, n=160.3 ± 2.41
Albumin, Week 12, n=160.6 ± 2.42
Total protein, Week 4, n=170.2 ± 3.23
Total protein, Week 8, n=15-0.1 ± 3.53
Total protein, Week 12, n=160.5 ± 4.31
SecondaryChange From Baseline in Calcium, Glucose, Potassium, Sodium and Urea Enzymatic Colorimetry at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of clinical chemistry parameters; calcium, glucose, potassium, sodium and urea enzymatic colorimetry (UEC) following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 14 and 29
Reported as:
Mean · Millimoles per Liter
Change From Baseline in Calcium, Glucose, Potassium, Sodium and Urea Enzymatic Colorimetry at Indicated Time Points (Oral Dose)
Millimoles per LiterCabotegravir Oral 30 mg
Calcium, Day 14-0.027722 ± 0.0905221
Calcium, Day 29-0.033267 ± 0.0774940
Glucose, Day 140.391654 ± 0.6929202
Glucose, Day 290.672288 ± 1.0302415
Potassium, Day 14-0.05 ± 0.296
Potassium, Day 29-0.04 ± 0.241
Sodium, Day 14-0.9 ± 1.53
Sodium, Day 29-0.3 ± 2.43
UEC, Day 14-0.2975 ± 0.97384
UEC, Day 29-0.2578 ± 1.14741
SecondaryChange From Baseline in Calcium, Glucose, Potassium, Sodium and UEC at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of clinical chemistry parameters; calcium, glucose, potassium, sodium and UEC following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Reported as:
Mean · Millimoles per Liter
Change From Baseline in Calcium, Glucose, Potassium, Sodium and UEC at Indicated Time Points (IM Dose)
Millimoles per LiterCabotegravir IM 600 mg
Calcium, Week 4, n=17-0.002935 ± 0.0763335
Calcium, Week 8, n=15-0.003327 ± 0.0610177
Calcium, Week 12, n=16-0.001559 ± 0.0666177
Glucose, Week 4, n=17-0.111020 ± 0.6467570
Glucose, Week 8, n=16-0.003469 ± 0.8073398
Glucose, Week 12, n=16-0.149183 ± 0.6402427
Potassium, Week 4, n=17-0.08 ± 0.260
Potassium, Week 8, n=16-0.07 ± 0.236
Potassium, Week 12, n=160.01 ± 0.379
Sodium, Week 4, n=17-0.4 ± 2.06
Sodium, Week 8, n=160.1 ± 1.77
Sodium, Week 12, n=16-0.6 ± 1.79
UEC, Week 4, n=17-0.5250 ± 1.01068
UEC, Week 8, n=16-0.6694 ± 1.20801
UEC, Week 12, n=16-0.3570 ± 1.18762
SecondaryChange From Baseline in Basophil Count, Eosinophil Count, Lymphocyte Count and Monocyte Count at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of hematology parameters; basophil count, eosinophil count, lymphocyte count and monocyte count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 14 and 29
Reported as:
Mean · Giga cells per Liter
Change From Baseline in Basophil Count, Eosinophil Count, Lymphocyte Count and Monocyte Count at Indicated Time Points (Oral Dose)
Giga cells per LiterCabotegravir Oral 30 mg
Basophils, Day 14, n=1-0.30 ± NA
Basophils, Day 29, n=2-0.05 ± 0.212
Eosinophils, Day 14, n=10.000 ± NA
Eosinophils, Day 29, n=20.100 ± 0.1414
Lymphocytes, Day 14, n=10.500 ± NA
Lymphocytes, Day 29, n=20.400 ± 0.1414
Monocytes, Day 14, n=10.000 ± NA
Monocytes, Day 29, n=2-0.100 ± 0.0000
SecondaryChange From Baseline in Basophil Count, Eosinophil Count, Lymphocyte Count and Monocyte Count at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of hematology parameters; basophil count, eosinophil count, lymphocyte count and monocyte count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 4 and 8
Reported as:
Mean · Giga cells per Liter
Change From Baseline in Basophil Count, Eosinophil Count, Lymphocyte Count and Monocyte Count at Indicated Time Points (IM Dose)
Giga cells per LiterCabotegravir IM 600 mg
Basophils, Week 4, n=30.03 ± 0.058
Basophils, Week 8, n=10.00 ± NA
Eosinophils, Week 4, n=30.000 ± 0.0000
Eosinophils, Week 8, n=10.000 ± NA
Lymphocytes, Week 4, n=30.073 ± 0.3607
Lymphocytes, Week 8, n=1-0.300 ± NA
Monocytes, Week 4, n=3-0.040 ± 0.2425
Monocytes, Week 8, n=10.000 ± NA
SecondaryChange From Baseline in Total Neutrophil Count at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of hematology parameter; total neutrophils count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 14 and 29
Reported as:
Mean · Giga cells per Liter
Change From Baseline in Total Neutrophil Count at Indicated Time Points (Oral Dose)
Giga cells per LiterCabotegravir Oral 30 mg
Day 14, n=9-0.353 ± 0.6194
Day 29, n=11-0.565 ± 1.1071
SecondaryChange From Baseline in Total Neutrophil Count at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of hematology parameters; total neutrophil count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Reported as:
Mean · Giga cells per Liter
Change From Baseline in Total Neutrophil Count at Indicated Time Points (IM Dose)
Giga cells per LiterCabotegravir IM 600 mg
Week 4, n=110.539 ± 0.9379
Week 8, n=80.010 ± 0.8206
Week 12, n=7-0.076 ± 0.7115
SecondaryChange From Baseline in Platelet Count and White Blood Cell (WBC) Count at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of hematology parameters; platelet count and WBC count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29
Reported as:
Mean · Giga cells per Liter
Change From Baseline in Platelet Count and White Blood Cell (WBC) Count at Indicated Time Points (Oral Dose)
Giga cells per LiterCabotegravir Oral 30 mg
Platelets, Day 1 (post-dose), n=139.0 ± NA
Platelets, Day 14, n=17-6.6 ± 30.83
Platelets, Day 29, n=188.7 ± 29.14
WBCs, Day 1, n=12.100 ± NA
WBCs, Day 14, n=17-0.056 ± 0.8815
WBCs, Day 29, n=18-0.263 ± 1.1894
SecondaryChange From Baseline in Platelet Count and WBC Count at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of hematology parameters; platelet count and WBC count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Reported as:
Mean · Giga cells per Liter
Change From Baseline in Platelet Count and WBC Count at Indicated Time Points (IM Dose)
Giga cells per LiterCabotegravir IM 600 mg
Platelets, Week 4, n=1711.7 ± 21.00
Platelets, Week 8, n=1612.0 ± 25.72
Platelets, Week 12, n=167.3 ± 18.34
WBCs, Week 4, n=17-0.053 ± 1.1486
WBCs, Week 8, n=16-0.085 ± 0.7777
WBCs, Week 12, n=16-0.159 ± 0.9395
SecondaryChange From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of hematology parameters; hemoglobin and MCHC following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29
Reported as:
Mean · Grams per Liter
Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at Indicated Time Points (Oral Dose)
Grams per LiterCabotegravir Oral 30 mg
Hemoglobin, Day 1 (post-dose), n=1-6.0 ± NA
Hemoglobin, Day 14, n=17-5.1 ± 7.60
Hemoglobin, Day 29, n=18-3.6 ± 6.93
MCHC, Day 1 (post-dose), n=1-8.0 ± NA
MCHC, Day 14, n=17-1.2 ± 6.93
MCHC, Day 29, n=181.3 ± 7.81
SecondaryChange From Baseline in Hemoglobin and MCHC at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of hematology parameters; hemoglobin and MCHC following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Reported as:
Mean · Grams per Liter
Change From Baseline in Hemoglobin and MCHC at Indicated Time Points (IM Dose)
Grams per LiterCabotegravir IM 600 mg
Hemoglobin, Week 4, n=17-0.8 ± 5.25
Hemoglobin, Week 8, n=160.8 ± 6.56
Hemoglobin, Week 12, n=161.4 ± 7.31
MCHC, Week 4, n=170.9 ± 7.39
MCHC, Week 8, n=16-0.8 ± 6.33
MCHC, Week 12, n=161.8 ± 6.84
SecondaryChange From Baseline in Mean Corpuscle Hemoglobin (MCH) at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of hematology parameter; MCH following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29
Reported as:
Mean · Picograms
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at Indicated Time Points (Oral Dose)
PicogramsCabotegravir Oral 30 mg
Day 1 (post-dose), n=1-0.90 ± NA
Day 14, n=17-0.22 ± 0.629
Day 29, n=18-0.01 ± 0.567
SecondaryChange From Baseline in MCH at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of hematology parameter; MCH following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Reported as:
Mean · Picograms
Change From Baseline in MCH at Indicated Time Points (IM Dose)
PicogramsCabotegravir IM 600 mg
Week 4, n=17-0.15 ± 0.292
Week 8, n=16-0.39 ± 0.584
Week 12, n=16-0.36 ± 0.778
SecondaryChange From Baseline in Mean Corpuscle Volume (MCV) at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of hematology parameter; MCV following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29
Reported as:
Mean · Femtoliters
Change From Baseline in Mean Corpuscle Volume (MCV) at Indicated Time Points (Oral Dose)
FemtolitersCabotegravir Oral 30 mg
Day 1 (post-dose), n=1-0.20 ± NA
Day 14, n=17-0.40 ± 1.052
Day 29, n=18-0.34 ± 1.303
SecondaryChange From Baseline in MCV at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of hematology parameter; MCV following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Reported as:
Mean · Femtoliters
Change From Baseline in MCV at Indicated Time Points (IM Dose)
FemtolitersCabotegravir IM 600 mg
Week 4, n=17-0.67 ± 1.771
Week 8, n=16-1.03 ± 1.799
Week 12, n=16-1.63 ± 1.861
SecondaryChange From Baseline in Hematocrit at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of hematology parameter; hematocrit following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit at Indicated Time Points (Oral Dose)
Proportion of red blood cells in bloodCabotegravir Oral 30 mg
Day 1 (post-dose), n=1-0.0060 ± NA
Day 14, n=17-0.0135 ± 0.02456
Day 29, n=18-0.0122 ± 0.02084
SecondaryChange From Baseline in Hematocrit at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of hematology parameter; hematocrit following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit at Indicated Time Points (IM Dose)
Proportion of red blood cells in bloodCabotegravir IM 600 mg
Week 4, n=17-0.0034 ± 0.01703
Week 8, n=160.0030 ± 0.02145
Week 12, n=160.0025 ± 0.02196
SecondaryChange From Baseline in Red Blood Cell (RBC) Count at Indicated Time Points (Oral Dose)

Blood samples were collected for the assessment of hematology parameter; RBC count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29
Reported as:
Mean · Trillion cells per liter
Change From Baseline in Red Blood Cell (RBC) Count at Indicated Time Points (Oral Dose)
Trillion cells per literCabotegravir Oral 30 mg
Day 1 (post-dose), n=1-0.050 ± NA
Day 14, n=17-0.126 ± 0.2813
Day 29, n=18-0.114 ± 0.2360
SecondaryChange From Baseline in RBC Count at Indicated Time Points (IM Dose)

Blood samples were collected for the assessment of hematology parameter; RBC count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Reported as:
Mean · Trillion cells per liter
Change From Baseline in RBC Count at Indicated Time Points (IM Dose)
Trillion cells per literCabotegravir IM 600 mg
Week 4, n=17-0.004 ± 0.1718
Week 8, n=160.087 ± 0.2129
Week 12, n=160.117 ± 0.2266
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time Points (Oral Dose)

SBP and DBP were measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 14 and 29
Reported as:
Mean · Millimeters of mercury
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time Points (Oral Dose)
Millimeters of mercuryCabotegravir Oral 30 mg
SBP, Day 14-1.3 ± 8.55
SBP, Day 29-1.0 ± 8.64
DBP, Day 14-0.9 ± 7.57
DBP, Day 290.5 ± 5.96
SecondaryChange From Baseline in SBP and DBP at Indicated Time Points (IM Dose)

SBP and DBP were measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52
Reported as:
Mean · Millimeters of mercury
Change From Baseline in SBP and DBP at Indicated Time Points (IM Dose)
Millimeters of mercuryCabotegravir IM 600 mg
SBP, Day 3, n=170.1 ± 10.15
SBP, Day 5, n=17-1.5 ± 10.44
SBP, Day 8, n=173.2 ± 13.18
SBP, Week 4, n=171.8 ± 12.11
SBP, Week 8, n=160.9 ± 9.23
SBP, Week 12, n=16-1.1 ± 11.69
SBP, Week 24, n=162.0 ± 12.88
SBP, Week 36, n=161.7 ± 11.44
SBP, Week 52, n=150.7 ± 13.08
DBP, Day 3, n=170.5 ± 4.11
DBP, Day 5, n=17-0.7 ± 4.69
DBP, Day 8, n=170.6 ± 5.36
DBP, Week 4, n=17-0.4 ± 5.20
DBP, Week 8, n=163.3 ± 5.65
DBP, Week 12, n=160.2 ± 4.46
DBP, Week 24, n=161.0 ± 4.98
DBP, Week 36, n=162.3 ± 5.47
DBP, Week 52, n=150.1 ± 9.23
SecondaryChange From Baseline in Pulse Rate at Indicated Time Points (Oral Dose)

Pulse rate was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 14 and 29
Reported as:
Mean · Beats per minute
Change From Baseline in Pulse Rate at Indicated Time Points (Oral Dose)
Beats per minuteCabotegravir Oral 30 mg
Day 14-1.0 ± 5.72
Day 292.4 ± 8.23
SecondaryChange From Baseline in Pulse Rate at Indicated Time Points (IM Dose)

Pulse rate was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52
Reported as:
Mean · Beats per minute
Change From Baseline in Pulse Rate at Indicated Time Points (IM Dose)
Beats per minuteCabotegravir IM 600 mg
Day 3, n=17-0.9 ± 10.51
Day 5, n=176.2 ± 7.66
Day 8, n=171.6 ± 9.06
Week 4, n=17-0.6 ± 7.40
Week 8, n=16-0.9 ± 7.85
Week 12, n=161.3 ± 11.80
Week 24, n=161.1 ± 6.87
Week 36, n=162.6 ± 11.07
Week 52, n=151.9 ± 10.59
SecondaryChange From Baseline in Body Temperature at Indicated Time Points (Oral Dose)

Body temperature was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 14 and 29
Reported as:
Mean · Degrees Celsius
Change From Baseline in Body Temperature at Indicated Time Points (Oral Dose)
Degrees CelsiusCabotegravir Oral 30 mg
Day 14-0.2 ± 0.54
Day 29-0.1 ± 0.46
SecondaryChange From Baseline in Body Temperature at Indicated Time Points (IM Dose)

Body temperature was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52
Reported as:
Mean · Degrees Celsius
Change From Baseline in Body Temperature at Indicated Time Points (IM Dose)
Degrees CelsiusCabotegravir IM 600 mg
Day 3, n=17-0.0 ± 0.36
Day 5, n=170.2 ± 0.52
Day 8, n=170.0 ± 0.37
Week 4, n=17-0.1 ± 0.31
Week 8, n=16-0.0 ± 0.47
Week 12, n=160.2 ± 0.37
Week 24, n=16-0.0 ± 0.39
Week 36, n=16-0.1 ± 0.58
Week 52, n=150.1 ± 0.61
SecondaryNumber of Participants With Abnormal Urinalysis Parameters Following Oral Administration of Cabotegravir

Urinalysis included assessment of pH, glucose, protein, blood and ketones by dipstick method. This analysis was not planned and data was not collected and not captured in the database.

Time frame:
Up to Day 29

No measurements were reported for this outcome.

SecondaryNumber of Participants With Abnormal Urinalysis Parameters Following IM Administration of Cabotegravir

Urinalysis included assessment of pH, glucose, protein, blood and ketones by dipstick method. This analysis was not planned and data was not collected and not captured in the database.

Time frame:
Up to Week 52

No measurements were reported for this outcome.

Adverse events

Collected over Non-SAEs and SAEs were collected from the start of study treatment up to Day 29 for Period 1 (Oral dose) and up to Week 52 for Period 2 (IM dose). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabotegravir Oral 30 mg0/19 (0%)0/19 (0%)10/19 (52.6%)
Cabotegravir IM 600 mg0/17 (0%)2/17 (11.8%)17/17 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventCabotegravir Oral 30 mgCabotegravir IM 600 mg
Pupils unequalEye disorders0/191/17
DysphagiaGastrointestinal disorders0/191/17
Urinary tract infectionInfections and infestations0/191/17
AphasiaNervous system disorders0/191/17
Cerebral haemorrhageNervous system disorders0/191/17
Migraine with auraNervous system disorders0/191/17
Serotonin syndromeNervous system disorders0/191/17
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/191/17
Post-traumatic stress disorderPsychiatric disorders0/191/17
DyspnoeaRespiratory, thoracic and mediastinal disorders0/191/17
Most frequent other events
Showing 10 of 44
Most frequent other events
EventCabotegravir Oral 30 mgCabotegravir IM 600 mg
Injection site painGeneral disorders0/1915/17
Gastroenteritis viralInfections and infestations3/190/17
Injection site erythemaGeneral disorders0/192/17
PyrexiaGeneral disorders0/192/17
DepressionPsychiatric disorders0/192/17
InsomniaPsychiatric disorders0/192/17
PalpitationsCardiac disorders0/192/17
HeadacheNervous system disorders0/192/17
Blood glucose increasedInvestigations2/190/17
FatigueGeneral disorders1/191/17

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg
Mean33.3 ± 9.12
Sex: Female, Male
Sex: Female, Male(Participants)Cabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg
Female10
Male9
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg
Asian - South East Asian Heritage1
Black or African American6
White - White/Caucasian/European Heritage12
09

Study locations

2 sites
  • GSK Investigational Site
    Baltimore, Maryland 21287-5554, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jul 2019, 28 months.

Results were first posted in Jun 2020, 10 months after primary completion.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 28 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2015
First posted
Jun 23, 2015
StartActual
Feb 27, 2017
Primary completionActual
Jul 25, 2019
CompletionActual
Jul 25, 2019
Results first posted
Jun 22, 2020
Last update
Jun 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02478463
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Jun 23, 2015
Start date
Feb 27, 2017
Primary completion
Jul 25, 2019
Completion
Jul 25, 2019
Results posted
Jun 22, 2020
Last update
Jun 22, 2020

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion